Literature DB >> 31321491

"Myocardial transit-time" (MyoTT): a novel and easy-to-perform CMR parameter to assess microvascular disease.

Grigorios Chatzantonis1, Michael Bietenbeck1, Anca Florian1, Claudia Meier1, Dennis Korthals1, Holger Reinecke1, Ali Yilmaz2.   

Abstract

BACKGROUND: Myocardial microvascular disease may occur during the disease course of different cardiac as well as systemic disorders. With the present study, we introduce a novel and easy-to-perform cardiovascular magnetic resonance (CMR) parameter named "myocardial transit-time" (MyoTT).
METHODS: N = 20 patients with known hypertrophic cardiomyopathy (HCM) and N = 20 control patients without relevant cardiac disease underwent dedicated CMR studies on a 1.5-T MR scanner. The CMR protocol comprised cine and late-gadolinium-enhancement (LGE) imaging as well as first-pass perfusion acquisitions at rest for MyoTT measurement. MyoTT was defined as the blood circulation time from the orifice of the coronary arteries to the pooling in the coronary sinus (CS), and accordingly measured as the temporal difference between the appearances of CMR contrast agent in the aortic root and the CS reflecting the transit-time of gadolinium in the myocardial microvasculature.
RESULTS: Patients with HCM had a significantly prolonged MyoTT compared to controls (11.0 (9.1-14.5) s vs. 6.5 (4.8-8.4) s, p < 0.001). This significant difference did not change when the individual heart rate was taken into consideration (MyoTT indexed, p < 0.001). Significant correlations were found between MyoTT and maximal left ventricular (LV) wall thickness (r = 0.771, p < 0.001), MyoTT and presence of LGE (r = 0.760, p < 0.001) as well as MyoTT and LV global longitudinal strain (r = 0.672, p < 0.001). ROC analysis resulted in an area-under-curve (AUC) of 0.90 for MyoTT and showed an optimal sensitivity/specificity cut-off of 7.85 s to differentiate HCM from controls.
CONCLUSION: "Myocardial transit-time" is a novel and easy-to-perform CMR parameter that allows a quick assessment of the extent of myocardial microvascular disease. This novel CMR parameter may open new vistas in the assessment of microvascular disease-not only in HCM patients. Future studies will show the usefulness and clinical relevance of this novel CMR parameter.

Entities:  

Keywords:  CMD; CMR; HCM; Microvascular disease; MyoTT; Myocardial perfusion

Mesh:

Substances:

Year:  2019        PMID: 31321491     DOI: 10.1007/s00392-019-01530-x

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  40 in total

1.  Global myocardial blood flow and global flow reserve measurements by MRI and PET are comparable.

Authors:  J W Koskenvuo; H Sakuma; P Niemi; J O Toikka; J Knuuti; H Laine; M Komu; M Kormano; M Saraste; J J Hartiala
Journal:  J Magn Reson Imaging       Date:  2001-03       Impact factor: 4.813

2.  Myocardial transit time. A new technic for evaluating coronary circulation. I. Effect of systemic blood pressure.

Authors:  H BERNSTEIN; R B SKELTON; H GOLD; D W IRVING; E CORDAY
Journal:  Am J Cardiol       Date:  1962-05       Impact factor: 2.778

3.  Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study.

Authors:  S E Reis; R Holubkov; A J Conrad Smith; S F Kelsey; B L Sharaf; N Reichek; W J Rogers; C N Merz; G Sopko; C J Pepine
Journal:  Am Heart J       Date:  2001-05       Impact factor: 4.749

4.  Attenuated coronary flow reserve and vascular remodeling in patients with hypertension and left ventricular hypertrophy.

Authors:  S Hamasaki; J Al Suwaidi; S T Higano; K Miyauchi; D R Holmes; A Lerman
Journal:  J Am Coll Cardiol       Date:  2000-05       Impact factor: 24.094

5.  Excess Cardiovascular Risk in Women Relative to Men Referred for Coronary Angiography Is Associated With Severely Impaired Coronary Flow Reserve, Not Obstructive Disease.

Authors:  Viviany R Taqueti; Leslee J Shaw; Nancy R Cook; Venkatesh L Murthy; Nishant R Shah; Courtney R Foster; Jon Hainer; Ron Blankstein; Sharmila Dorbala; Marcelo F Di Carli
Journal:  Circulation       Date:  2016-11-14       Impact factor: 29.690

Review 6.  Coronary Physiology Beyond Coronary Flow Reserve in Microvascular Angina: JACC State-of-the-Art Review.

Authors:  K Lance Gould; Nils P Johnson
Journal:  J Am Coll Cardiol       Date:  2018-11-27       Impact factor: 24.094

7.  Functional changes in coronary microcirculation after valve replacement in patients with aortic stenosis.

Authors:  Kim Rajappan; Ornella E Rimoldi; Paolo G Camici; Nicholas G Bellenger; Dudley J Pennell; Desmond J Sheridan
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

8.  High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries).

Authors:  Peter Ong; Anastasios Athanasiadis; Gabor Borgulya; Heiko Mahrholdt; Juan Carlos Kaski; Udo Sechtem
Journal:  J Am Coll Cardiol       Date:  2012-02-14       Impact factor: 24.094

Review 9.  Coronary microvascular dysfunction: an update.

Authors:  Filippo Crea; Paolo G Camici; Cathleen Noel Bairey Merz
Journal:  Eur Heart J       Date:  2013-12-23       Impact factor: 29.983

10.  Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy.

Authors:  J E Brush; R O Cannon; W H Schenke; R O Bonow; M B Leon; B J Maron; S E Epstein
Journal:  N Engl J Med       Date:  1988-11-17       Impact factor: 91.245

View more
  2 in total

1.  Coronary microvascular disease in hypertrophic and infiltrative cardiomyopathies.

Authors:  Andreas A Giannopoulos; Ronny R Buechel; Philipp A Kaufmann
Journal:  J Nucl Cardiol       Date:  2022-08-01       Impact factor: 3.872

2.  Diagnostic value of the novel CMR parameter "myocardial transit-time" (MyoTT) for the assessment of microvascular changes in cardiac amyloidosis and hypertrophic cardiomyopathy.

Authors:  Grigorios Chatzantonis; Michael Bietenbeck; Anca Florian; Claudia Meier; Philipp Stalling; Dennis Korthals; Holger Reinecke; Ali Yilmaz
Journal:  Clin Res Cardiol       Date:  2020-05-05       Impact factor: 5.460

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.